{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:06:55Z","timestamp":1771308415790,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) remains a major clinical challenge, with postoperative recurrence risk varying substantially among patients. Emerging evidence suggests that serum biomarkers, including \u03b1-methylacyl-CoA racemase (AMACR) and zinc finger protein-like 1 (ZFPL1), may provide additional prognostic information beyond conventional clinicopathological factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This single-center retrospective study included 115 patients with PCa who underwent radical prostatectomy. Serum AMACR and ZFPL1 levels were analyzed in combination with clinicopathological variables. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of recurrence. A risk nomogram was constructed, and model performance was evaluated using receiver operating characteristic (ROC) curve analysis and Kaplan\u2013Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Poor postoperative outcomes were significantly associated with advanced age, lymph node metastasis, higher TNM stage, poor tumor differentiation, and higher Gleason score. Serum AMACR and ZFPL1 levels were significantly elevated in patients who experienced recurrence. Multivariate analysis identified both biomarkers as independent predictors of recurrence. The resulting nomogram demonstrated strong discriminative performance and stable predictive accuracy across multiple postoperative time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated serum AMACR and ZFPL1 levels independently predict recurrence following radical prostatectomy in patients with PCa. The proposed nomogram integrates molecular and clinicopathological factors to provide accurate postoperative risk stratification, supporting individualized follow-up and management, with robust performance observed up to 3 years after surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1625125","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:17:59Z","timestamp":1771305479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["AMACR and ZFPL1 serum biomarkers enhance precision in predicting postoperative prostate cancer outcomes"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Urology, Qilu Hospital, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renguang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Urology, Jinan Seventh People\u2019s Hospital","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Qilu Hospital, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Jinan Seventh People\u2019s Hospital","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangli","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Urology, Qilu Hospital, Shandong University","place":["Jinan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51722","article-title":"Modern paradigms for prostate cancer detection and management","volume":"217","author":"Williams","year":"2022","journal-title":"Med J Aust"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: A randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26491","article-title":"Functional outcomes after localized prostate cancer treatment","volume":"331","author":"Al Hussein Al Awamlh","year":"2024","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.08.030","article-title":"Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial","volume":"86","author":"van As","year":"2024","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02236-8","article-title":"A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients","volume":"128","author":"Ebrahimizadeh","year":"2023","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04383-2","article-title":"Magnetic resonance imaging (MRI) for local staging before salvage radical prostatectomy: a meta-analysis","volume":"41","author":"Zapala","year":"2023","journal-title":"World J Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/biom15010017","article-title":"Atypical metastases from prostate cancer: alpha-methylacyl-coenzyme A racemase (AMACR) as a potential molecular target in prostate-specific membrane antigen-negative prostate adenocarcinoma","volume":"15","author":"Badrane","year":"2024","journal-title":"Biomolecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"532 e531","DOI":"10.1016\/j.urolonc.2018.09.010","article-title":"Semen AMACR protein as a novel method for detecting prostate cancer","volume":"36","author":"Etheridge","year":"2018","journal-title":"Urol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/1389200218666170518161140","article-title":"Urinary biomarkers for prostate cancer","volume":"18","author":"Giunchi","year":"2017","journal-title":"Curr Drug Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gene.2018.07.053","article-title":"RING domain of zinc finger protein like 1 is essential for cell proliferation in endometrial cancer cell line RL95-2","volume":"677","author":"Cai","year":"2018","journal-title":"Gene"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107162","article-title":"The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer","volume":"203","author":"Wang","year":"2024","journal-title":"Pharmacol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/biomedicines11061552","article-title":"Novel histopathological biomarkers in prostate cancer: implications and perspectives","volume":"11","author":"Kielb","year":"2023","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.386","article-title":"Prediction of early prostate cancer recurrence using a liquid biopsy approach","volume":"41","author":"Rahbar","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"601 e601","DOI":"10.1016\/j.urolonc.2020.02.009","article-title":"Surface-enhanced Raman spectroscopy of preoperative serum samples predicts Gleason grade group upgrade in biopsy Gleason grade group 1 prostate cancer","volume":"38","author":"Qian","year":"2020","journal-title":"Urol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e17031","article-title":"Clinical markers of successful liquid biopsy-based genomic profiling in veterans with prostate cancer","volume":"40","author":"Guo","year":"2022","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01881-9","article-title":"Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges","volume":"127","author":"Trujillo","year":"2022","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3877\/cma.j.issn.1674-3253.2022.06.001","article-title":"Interpretation of updated key points in 2022 European Urological Association Guidelines for diagnosis and treatment of prostate cancer","volume":"16","author":"Huang","year":"2022","journal-title":"Chin J Endourol (Electronic Edition)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2013.01.001","article-title":"alpha-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S","volume":"52","author":"Lloyd","year":"2013","journal-title":"Prog Lipid Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/CBM-200939","article-title":"Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer","volume":"31","author":"Yan","year":"2021","journal-title":"Cancer biomark"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/cells11244026","article-title":"Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer","volume":"11","author":"Pardella","year":"2022","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","article-title":"Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment","volume":"12","author":"Zhang","year":"2024","journal-title":"biomark Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17648","article-title":"Role of tumor microenvironment in tumorigenesis","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.prnil.2020.07.001","article-title":"Combined alpha-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells","volume":"9","author":"Yoshizawa","year":"2021","journal-title":"Prostate Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.40","article-title":"ZFPL1, a novel ring finger protein required for cis-Golgi integrity and efficient ER-to-Golgi transport","volume":"27","author":"Chiu","year":"2008","journal-title":"EMBO J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3892\/ijo.2023.5486","article-title":"Zinc finger protein\u2212like 1 is a novel neuroendocrine biomarker for prostate cancer","volume":"66","author":"Masud","year":"2025","journal-title":"Int J Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3390\/cancers13112795","article-title":"Cell plasticity and prostate cancer: the role of epithelial-mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance","volume":"13","author":"Papanikolaou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1272-5","article-title":"Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach","volume":"461","author":"Annenkov","year":"2012","journal-title":"Virchows Arch"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.110668","article-title":"Emerging biomarkers for the diagnosis and prognosis of prostate cancer","volume":"54","author":"Sardana","year":"2008","journal-title":"Clin Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.3390\/cancers13164162","article-title":"Integrating serum biomarkers into prediction models for biochemical recurrence following radical prostatectomy","volume":"13","author":"Moghaddam","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70555","DOI":"10.1111\/jcmm.70555","article-title":"Discovery of lncRNA-based prosRISK score in serum as potential biomarkers for improved accuracy of prostate cancer detection","volume":"29","author":"Jiang","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B36","article-title":"Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis","volume":"64","author":"Shariat","year":"2011","journal-title":"Arch Esp Urol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.juro.2009.01.110","article-title":"A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer","volume":"181","author":"Ouyang","year":"2009","journal-title":"J Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1625125\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:01Z","timestamp":1771305481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1625125\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1625125"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1625125","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1625125"}}